Lack of association between genetic polymorphisms and risk of ischemic stroke: evidence from meta-analyses.

BACKGROUND

In recent years, there has been substantial research evaluating the relationship between arachidonate 5-lipoxygenase-activating protein () polymorphisms and ischemic stroke (IS). The objective of this study was to systematically review and analyze the existing evidence.

METHODS

A comprehensive search of major electronic databases for studies published between 1990 and 2018 was carried out. Data were synthesized as OR and 95% CI using fixed-effects and random-effects models.

RESULTS

A total of 30 studies were available for analysis. The aggregate sample size across all studies was 32,782 (16,294 cases and 16,488 controls). We found no association of the rs10507391 (OR=1.03 for A allele vs T allele; 95% CI: 0.93-1.14; =0.557), rs4769874 (OR=1.13 for A allele vs G allele; 95% CI: 1.00-1.28; =0.050), rs9551963 (OR=1.03 for A allele vs C allele; 95% CI: 0.96-1.11; =0.372), rs17222814 (OR=1.09 for A allele vs G allele; 95% CI: 0.96-1.24; =0.195), rs17222919 (OR=0.89 for G allele vs T allele; 95% CI: 0.75-1.06; =0.175), and rs4073259 (OR=1.20 for A allele vs G allele; 95% CI: 1.00-1.45; =0.056) polymorphisms with IS risk. Haplotype analysis also did not yield significant findings for the HapA (rs17222814G-rs10507391T-rs4769874G-rs9551963A; OR=1.20; 95% CI: 0.91-1.56; =0.192) and HapB (rs17216473A-rs10507391A-rs9315050A-rs17222842G; OR=1.11; 95% CI: 0.90-1.38; =0.339) haplotypes.

CONCLUSION

Current evidence does not support an association of rs10507391, rs4769874, rs9551963, rs17222814, rs17222919, rs4073259, and HapA and HapB with IS risk.